YAP-TEAD Is Essential for PPARα-Mediated Hepatomegaly in Mice

Study Background and Research Question

The peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor central to lipid metabolism regulation, energy homeostasis, and the hepatic response to metabolic stress. PPARα activation by selective agonists like WY-14643 (Pirinixic Acid) is known to induce hepatomegaly—a reversible liver enlargement characterized by increased hepatocyte size and proliferation—as well as to enhance liver regenerative capacity post-injury (source: internal_article). However, the downstream signaling pathways that translate PPARα activation into hepatic growth and regeneration remain incompletely understood. The current study addresses the specific question: Does the transcriptional co-activator YAP, in complex with TEAD, mediate the hepatic effects of PPARα activation in mice? (source: reference_paper).

Key Innovation from the Reference Study

This work is the first to combine liver-specific genetic deletions of PPARα and YAP with pharmacological activation using WY-14643 to directly interrogate the requirement for the YAP-TEAD axis in PPARα-induced hepatomegaly and regeneration. By integrating loss-of-function approaches for both PPARα and YAP, and by inhibiting YAP-TEAD interaction pharmacologically, the study advances our mechanistic understanding of how nuclear receptor signaling converges on organ size regulation and hepatic repair (source: reference_paper).

Methods and Experimental Design Insights

The study utilized a comprehensive experimental design, combining the following models and interventions:

• Animal models: Male C57BL/6 mice, hepatocyte-specific Pparα-deficient (PparaΔHep), and Yap-deficient (YapΔHep) mice.
• PPARα activation: Intraperitoneal injection of WY-14643 (100 mg/kg/day) for 10 days to induce PPARα signaling (source: reference_paper).
• Partial hepatectomy (PHx): Performed to examine regeneration post-liver injury.
• Pharmacological YAP-TEAD inhibition: Verteporfin administered to block YAP-TEAD interaction.
• YAP knockdown: Achieved via AAV-shRNA delivery targeting Yap.
• Histology and molecular analyses: Hematoxylin and eosin (H&E) staining, β-catenin and KI67 immunohistochemistry, ImageJ-based hepatocyte size quantification, and qPCR for gene expression.
• Biochemical assays: Measurement of serum ALT, AST, ALP, albumin, total bile acids, and bilirubin.

This multi-pronged approach allowed the dissection of the respective contributions of PPARα and YAP-TEAD to liver growth and regeneration (source: reference_paper).

Protocol Parameters

• assay: PPARα activation in vivo | value_with_unit: 100 mg/kg/day WY-14643 (IP) for 10 days | applicability: murine induction of PPARα-mediated hepatomegaly | rationale: matches protocol for robust pharmacologic activation | source_type: reference_paper
• assay: PHx (partial hepatectomy) | value_with_unit: removal of ~70% of liver | applicability: liver regeneration studies | rationale: standard model for hepatic regenerative response | source_type: reference_paper
• assay: YAP-TEAD inhibition | value_with_unit: 100 mg/kg/day verteporfin (IP) for 5–10 days | applicability: blockade of YAP-TEAD transcriptional activity in vivo | rationale: pharmacologic confirmation of pathway dependency | source_type: reference_paper
• assay: Immunohistochemistry (KI67, β-catenin) | value_with_unit: per manufacturer’s instructions | applicability: proliferation and Wnt-pathway readouts | rationale: quantification of hepatocyte proliferation and size | source_type: reference_paper
• assay: WY-14643 solubilization for in vivo use | value_with_unit: soluble in DMSO (≥16.2 mg/mL), insoluble in water | applicability: preparation for rodent injections | rationale: ensures appropriate delivery and bioavailability | source_type: product_spec

Core Findings and Why They Matter

The study’s results provide robust evidence that the YAP-TEAD complex is indispensable for the hepatic effects of PPARα activation:

• WY-14643 induces hepatomegaly and liver regeneration in wild-type mice, but not in PparaΔHep or YapΔHep mice, demonstrating that both PPARα and YAP are required for these phenotypes (source: reference_paper).
• Pharmacological inhibition of YAP-TEAD with verteporfin prevents WY-14643-induced liver growth, confirming the necessity of this pathway downstream of PPARα (source: reference_paper).
• Histological analyses show increased hepatocyte size and proliferation (KI67+ cells) with WY-14643, effects blunted by genetic or pharmacologic YAP inactivation.
• qPCR and biochemical markers confirm the activation of PPARα target gene expression and restoration of liver function post-PHx in a YAP-dependent manner.

These findings underscore a mechanistic link between metabolic signaling (PPARα) and organ size control (YAP-TEAD), providing a new framework for interpreting how metabolic stimuli can drive hepatic adaptation and regeneration (source: reference_paper).

Comparison with Existing Internal Articles

Previous reviews and translational perspectives have highlighted WY-14643 (Pirinixic Acid) as a key tool for interrogating PPARα-dependent pathways in both metabolic disorder research and tumor microenvironment studies (source: internal_article; internal_article). However, those articles focused primarily on the metabolic and immunological consequences of PPARα activation—such as insulin sensitivity enhancement, lipid metabolism regulation, and anti-inflammatory effects in endothelial cells—without directly probing the YAP-TEAD axis or its requirement for liver regenerative outcomes. This reference study uniquely bridges a gap by demonstrating that PPARα-driven hepatomegaly is contingent upon YAP-TEAD signaling, thus advancing the conceptual framework for future studies that wish to modulate liver size and repair via metabolic pathways.

Limitations and Transferability

While the study’s genetic and pharmacologic approaches are rigorous, several limitations are notable:

• The work is restricted to murine models, and the applicability of these findings to human liver physiology, particularly in disease contexts such as non-alcoholic fatty liver disease (NAFLD) or regeneration after clinical resection, remains to be validated (source: workflow_recommendation).
• Only a single PPARα agonist (WY-14643) and a single YAP-TEAD inhibitor (verteporfin) were employed; whether similar mechanisms operate with other PPARα ligands or in chronic disease models is unaddressed.
• The study does not fully elucidate the downstream targets of YAP-TEAD responsible for mediating hepatocyte proliferation and growth.

Despite these caveats, the evidence supports a foundational role for the YAP-TEAD module in PPARα-induced hepatic adaptation.

Research Support Resources

For researchers seeking to further investigate PPARα-mediated signaling pathways—including studies on insulin sensitivity enhancement, anti-inflammatory effects in endothelial cells, or liver regeneration—the selective PPARα agonist WY-14643 (Pirinixic Acid) (SKU A4305, APExBIO) is widely used in preclinical workflows (source: product_spec). Its established activity profile and characterization in both metabolic and regenerative models make it a suitable reagent for robust, reproducible studies in this domain. For detailed mechanistic or translational protocol guidance, readers may also consult recent reviews and best practice guides (internal_article).